Skip to content
My WebMD Sign In, Sign Up

Announcements

Medicare Donut Hole Rebate Checks on the Way

Have questions about the new health care reform changes? Submit them here.

PERSONALIZED MEDICINE IN LUNG CANCER
avatar
An_206445 posted:
The results summarized by Oxnard and Miller show that genetic testing is critical for clinical decision-making in this cancer. Depending on the population, the proportion of NSCLC patients who have EGFR-activating mutations may be in the range of 15% to 40%. Is it possible that the remaining set of patients have other genetic changes that might help us find a suitable treatment? It has been discovered that subsets of NSCLC patients have mutations in BRAF, mutations resulting in activation of the AKT pathway, amplification of ErbB2, amplification of MET, or translocation of EML and ALK4. Drugs that specifically target these changes are either available or in clinical trials for this or other tumor types.
Was this Helpful?
3 of 5 found this helpful
Reply


Helpful Tips

Terminal lung cancer I think doctor is wrong about chemo
My husband is 74. Just diagnosed 4 weeks ago. With small cell lung cancer. It has spread to his bones and spot on his liver. He had his ... More
Was this Helpful?
16 of 25 found this helpful

Related Drug Reviews

  • Drug Name User Reviews

Report Problems to the
Food and Drug Administration

FDAYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.